US FDA's inaugural biosimilar review bumpier than first appeared

Sue Sutter explains how the US Food and Drug Administration's handling of issues around protein content differences, statistical analyses of quality data and immunogenicity testing for Sandoz's Zarxio may prove instructive for future 351(k) applicants.